Author

E. Cannas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. J. Arribas· 3 shared D. Rossi· 3 shared F. Bertoni· 3 shared F. Spriano· 3 shared L. Cascione· 3 shared A. Stathis· 2 shared C. Tarantelli· 2 shared E. Gaudio· 2 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. J. Arribas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

F. Spriano, L. Cascione, J. Sgrignani, N. Bendik, S. Napoli, G. Sartori, E. Cannas, T. Gong, A. J. Arribas, M. Pizzi, D. Rossi, D. F. Robbiani, A. Cavalli, F. Bertoni

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology

Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

C. Tarantelli, D. Wald, N. Munz, F. Spriano, A. Bruscaggin, E. Cannas, L. Cascione, E. Gaudio, A. J. Arribas, S. Manjappa, G. Golino, L. Scalise, E. Zucca, A. Stathis, P. H. Van Berkel, , F. Bertoni

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

bioRxiv · Aug 17, 2023 · PreprintCancer Biology

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

A. J. Arribas, S. Napoli, L. Cascione, L. Barnabei, G. Sartori, E. Cannas, E. Gaudio, C. Tarantelli, A. A. Mensah, F. Spriano, A. Zucchetto, F. M. Rossi, A. Rinaldi, M. Castro de Moura, S. Jovic, , F. Bertoni

This study identifies ERBB4-mediated signaling as a mechanism of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms and shows that targeting ERBB signaling can restore sensitivity.

bioRxiv · Jan 1, 2023Cancer Biology